BMEA
HEALTHCAREBiomea Fusion Inc
AI Insight
What's Moving BMEA Today?
No stock-specific AI insight has been generated for BMEA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.87$2.99
$1.23
Fundamentals
Market Cap$85M
P/E Ratio—
EPS$-0.55
Dividend Yield—
Dividend / Share—
ROE-189.4%
Profit Margin—
Debt / Equity—
Trading
Volume460K
Avg Volume (10D)—
Shares Outstanding72.3M
BMEA News
21 articles- Biomea Fusion Inc (BMEA) Financial Health: Profitability & Balance Sheet AnalysisTradingKey·Jun 20, 2026
- Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 StudyGlobeNewswire Inc.·Jun 5, 2026
- Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in ObesityYahoo Finance·Jun 3, 2026
- Biomea Fusion to Participate at Upcoming Investor ConferencesYahoo Finance·May 12, 2026
- Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate HighlightsInvesting News Network·May 11, 2026
- Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific SessionsYahoo Finance·May 5, 2026
- Biomea Fusion Status Update: Experts Discuss Icovamenib’s Promise Ahead of ADA 2026Marketbeat·May 5, 2026
- Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with IcovamenibMarketbeat·Apr 28, 2026
- Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib TreatmentYahoo Finance·Apr 27, 2026
- Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care TherapiesGlobeNewswire Inc.·Mar 31, 2026
- Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity ReadoutsMarketbeat·Mar 30, 2026
- Biomea Fusion Teases Q2 Phase 1 Data for Oral GLP-1 BMF-650, Advances Icovamenib in DiabetesMarketbeat·Mar 30, 2026
- Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?Yahoo Finance·Mar 27, 2026
- Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial ResultsYahoo Finance·Mar 25, 2026
- Biomea Fusion Reports Full Year 2025 Financial Results and Corporate HighlightsYahoo Finance·Mar 24, 2026
- Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026Yahoo Finance·Mar 14, 2026
- Biomea Fusion Details Diabetes, Obesity Pipeline at Citizens Conference, Sees Cash Runway to Q1 2027Marketbeat·Mar 13, 2026
- Biomea Fusion Spotlights Durable Diabetes Data, Oral GLP-1 Weight-Loss Program at Oppenheimer Conf.Marketbeat·Feb 27, 2026
- Biomea Fusion, Inc.'s (NASDAQ:BMEA) largest shareholders are retail investors with 55% ownership, institutions own 38%Yahoo Finance·Jan 24, 2026
- Rodman & Renshaw Initiates Biomea Fusion (BMEA) at Buy with $8 Price TargetYahoo Finance·Jan 19, 2026
- Biomea Fusion Spotlights Diabetes, Obesity Pipeline at JPMorgan Conference, Sets 2026 MilestonesMarketbeat·Jan 15, 2026
All 21 articles loaded
Price Data
Open$1.23
Previous Close$1.23
Day High$1.29
Day Low$1.22
52 Week High$2.99
52 Week Low$0.87
52-Week Range
$0.87$2.99
$1.23
Fundamentals
Market Cap$85M
P/E Ratio—
EPS$-0.55
Dividend Yield—
Dividend / Share—
ROE-189.4%
Profit Margin—
Debt / Equity—
Trading
Volume460K
Avg Volume (10D)—
Shares Outstanding72.3M
About Biomea Fusion Inc
Biomea Fusion, Inc., a biopharmaceutical company, is focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company is headquartered in Redwood City, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—